Publication
What M&A trends will transform the 2024 insurance landscape?
It is widely accepted that 2023 was one of the worst years in recent memory for M&A activity.
Author:
Canada | Publication | March 11, 2020 4 PM ET
COVID-19, a new disease caused by the novel coronavirus, has a confirmed presence in over 100 countries and dominates the global media. It already has been a formidable economic disrupter and poses current and future challenges for Canadian businesses.
What are the legal duties of corporate Boards in responding to this unique challenge? Canadian statutes generally charge Boards with the duty to manage, or supervise the management of, the business and affairs of the corporation. Directors have a fiduciary duty to act in good faith with a view to the best interests of the corporation and a duty to act with the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances. In fulfilling their duties, directors may take into account the impact of their decisions on the interests of various corporate stakeholders. Their decisions are not judged from a standard of perfection, but must represent a reasonable exercise of business judgment.
How can Boards fulfil these duties in addressing COVID-19 challenges? There is no single blueprint that could possibly address the risk for all businesses. Each corporation, depending on the nature of its business, will experience a unique impact caused directly or indirectly by COVID-19. The Board’s responsibility is to oversee and monitor the risk and the corporation’s response to the risk. A prudent Board will ensure that: (i) the appropriate senior management report to the Board on key risks; (ii) the Board understands those key risks; (iii) professional advisers assist, if necessary and appropriate, in identifying, managing and mitigating risk; (iv) a contingency plan is put in place for foreseeable scenarios; and (v) the Board monitors the ongoing implementation of its decisions and guidance and remains sufficiently flexible to respond to the evolving situation. No list could be comprehensive, but relevant considerations could include:
Publication
It is widely accepted that 2023 was one of the worst years in recent memory for M&A activity.
Publication
The ongoing conflicts and further geopolitical tensions in Eastern Europe and the Middle East, coupled with upcoming elections in a number of key countries including the US and the UK, make 2024 challenging to predict what impact this will have on the insurance sector.
Publication
On 6 September 2022, the European Commission (EC) prohibited Illumina’s acquisition of Grail, bringing to an end the administrative stage of a legal saga that has attracted interest beyond competition law specialists.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023